1. Home
  2. JZXN vs INDP Comparison

JZXN vs INDP Comparison

Compare JZXN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JZXN

Jiuzi Holdings Inc.

N/A

Current Price

$2.35

Market Cap

16.2M

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$2.21

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JZXN
INDP
Founded
2019
2000
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
4.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
JZXN
INDP
Price
$2.35
$2.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
650.1K
41.8K
Earning Date
03-05-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$97,465.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.12
$1.65
52 Week High
$312.80
$47.60

Technical Indicators

Market Signals
Indicator
JZXN
INDP
Relative Strength Index (RSI) 59.32 42.80
Support Level $2.12 $2.39
Resistance Level $2.78 $2.94
Average True Range (ATR) 0.76 0.23
MACD 0.27 0.04
Stochastic Oscillator 26.63 27.85

Price Performance

Historical Comparison
JZXN
INDP

About JZXN Jiuzi Holdings Inc.

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: